These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35421957)

  • 1. Proteomics analysis: inhibiting the expression of P62 protein by chloroquine combined with dacarbazine can reduce the malignant progression of uveal melanoma.
    Fei X; Xie X; Qin R; Wang A; Meng X; Sun F; Zhao Y; Jiang D; Chen H; Huang Q; Ji X; Wang Z
    BMC Cancer; 2022 Apr; 22(1):408. PubMed ID: 35421957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor efficacy of VP22-CD/5-FC suicide gene system mediated by lentivirus in a murine uveal melanoma model.
    Liu S; Song W; Liu F; Zhang J; Zhu S
    Exp Eye Res; 2018 Jul; 172():144-151. PubMed ID: 29660328
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Li P; He J; Yang Z; Ge S; Zhang H; Zhong Q; Fan X
    Autophagy; 2020 Jul; 16(7):1186-1199. PubMed ID: 31462126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ubiquitination and degradation of MGMT by TRIM72 increases the sensitivity of uveal melanoma cells to Dacarbazine treatment.
    Li X; Yang C; Luo N; Yang Y; Guo Y; Chen P; Cun B
    Cancer Biomark; 2022; 34(2):275-284. PubMed ID: 34958003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma
    Zhou J; Jin B; Jin Y; Liu Y; Pan J
    Theranostics; 2017; 7(6):1447-1462. PubMed ID: 28529629
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Meng Z; Chen Y; Wu W; Yan B; Zhang L; Chen H; Meng Y; Liang Y; Yao X; Luo J
    Front Immunol; 2022; 13():754645. PubMed ID: 35281030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of survival-related genes and a novel gene-based prognostic signature involving the tumor microenvironment of uveal melanoma.
    Lei S; Zhang Y
    Int Immunopharmacol; 2021 Jul; 96():107816. PubMed ID: 34162166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting primary and metastatic uveal melanoma with a G protein inhibitor.
    Onken MD; Makepeace CM; Kaltenbronn KM; Choi J; Hernandez-Aya L; Weilbaecher KN; Piggott KD; Rao PK; Yuede CM; Dixon AJ; Osei-Owusu P; Cooper JA; Blumer KJ
    J Biol Chem; 2021; 296():100403. PubMed ID: 33577798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic landscape of adaptive immune resistance signatures and infiltrating immune cells in the tumor microenvironment of uveal melanoma.
    Wang Y; Xu Y; Dai X; Lin X; Shan Y; Ye J
    Exp Eye Res; 2020 Jul; 196():108069. PubMed ID: 32439398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor.
    Wang Y; Liu M; Jin Y; Jiang S; Pan J
    Cancer Lett; 2017 Aug; 400():47-60. PubMed ID: 28455241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pristimerin effectively inhibits the malignant phenotypes of uveal melanoma cells by targeting NF‑κB pathway.
    Zhang B; Zhang J; Pan J
    Int J Oncol; 2017 Sep; 51(3):887-898. PubMed ID: 28766683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative proteomic dataset of whole protein in three melanoma samples of 92.1, 92.1-A and 92.1-B.
    Fei X; Xie X; Ji X; Tian H; Sun F; Jiang D; Wang Z; Huang Q
    Data Brief; 2022 Dec; 45():108592. PubMed ID: 36164296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of RASSF1A in uveal melanoma.
    Dratviman-Storobinsky O; Cohen Y; Frenkel S; Merhavi-Shoham E; El SD; Binkovsky N; Pe'er J; Goldenberg-Cohen N
    Invest Ophthalmol Vis Sci; 2012 Oct; 53(6):2611-9. PubMed ID: 22447862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide CRISPR knockout screening identified G protein pathway suppressor 2 as a novel tumor suppressor for uveal melanoma metastasis.
    Shi S; Chen H; Wang H; Wan J; Shi Y; Li J; Wang S; Shi J; Lv J; Wu T; Wang L; Sun F
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3349-3360. PubMed ID: 35941228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.
    Calipel A; Landreville S; De La Fouchardière A; Mascarelli F; Rivoire M; Penel N; Mouriaux F
    Clin Exp Metastasis; 2014 Jun; 31(5):553-64. PubMed ID: 24652072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study.
    Schinzari G; Rossi E; Cassano A; Dadduzio V; Quirino M; Pagliara M; Blasi MA; Barone C
    Melanoma Res; 2017 Dec; 27(6):591-595. PubMed ID: 29076951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors.
    Némati F; Sastre-Garau X; Laurent C; Couturier J; Mariani P; Desjardins L; Piperno-Neumann S; Lantz O; Asselain B; Plancher C; Robert D; Péguillet I; Donnadieu MH; Dahmani A; Bessard MA; Gentien D; Reyes C; Saule S; Barillot E; Roman-Roman S; Decaudin D
    Clin Cancer Res; 2010 Apr; 16(8):2352-62. PubMed ID: 20371695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neddylation Blockade Diminishes Hepatic Metastasis by Dampening Cancer Stem-Like Cells and Angiogenesis in Uveal Melanoma.
    Jin Y; Zhang P; Wang Y; Jin B; Zhou J; Zhang J; Pan J
    Clin Cancer Res; 2018 Aug; 24(15):3741-3754. PubMed ID: 29233905
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of Long-term Serial Passaging on the Characteristics and Properties of Cell Lines Derived From Uveal Melanoma Primary Tumors.
    Mouriaux F; Zaniolo K; Bergeron MA; Weidmann C; De La Fouchardière A; Fournier F; Droit A; Morcos MW; Landreville S; Guérin SL
    Invest Ophthalmol Vis Sci; 2016 Oct; 57(13):5288-5301. PubMed ID: 27723895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.